Abstract: ArkBIo, a China-based near-commercial-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors. In our previous note, we looked at the company’s core products, AK0529 and AK3280. We also looked at the company’s pre-IPO investors and management team. In this note, we look at updates in its latest prospectus and review the competitive landscape of its core products.
SUNSHINE LAKE PHARMA, JUNSHI BIO, Enanta Pharmaceuticals
Interested in the full report? Get in touch with our team.